In 2026, several novel agents and approaches are poised to reshape clinical practice. This feature article highlights key breakthroughs and…

On August 6, 2025, the U.S. Food and Drug Administration (FDA) approved fremanezumab for the preventive treatment of episodic migraine in…

On April 30, 2025, the U.S. Food and Drug Administration (FDA) approved nipocalimab, a human neonatal Fc receptor (FcRn)-blocking monoclonal…

Explore the key abstracts we’re most excited to hear about at the 77th American Academy of Neurology (AAN) Annual Meeting,…

On February 4, 2025, the U.S. Food and Drug Administration (FDA) approved ONAPGO (apomorphine hydrochloride infusion), formerly known as SPN-830,…

On January 30, 2025, the U.S. Food and Drug Administration (FDA) approved AXS-07, a novel, oral medication for the acute…

On October 17, 2024, AbbVie announced the U.S. Food and Drug Administration (FDA) approval of foslevodopa-foscarbidopa, marking the first and…

The European Academy of Neurology (EAN) recently published its first guideline on the management of amyotrophic lateral sclerosis (ALS), in…